Top

BY Clayton Boldt, Ph.D.

Scientific discoveries are essential to driving advances in cancer care. From better screening and diagnostic techniques to innovative new therapies and survivorship programs — all rely on impactful research. 

That is why MD Anderson is focused on Breakthroughs as a central theme of our Strategy. Discovery research is the engine for progress in our mission to end cancer and to maximize our impact on humanity. 

...

As a member of MD Anderson's Pre-Cancer Atlas team, Melinda Yates, Ph.D., and her colleagues have been able to move quickly to implement new technologies to identify molecular features of uterine cancer development and response to hormone treatment.

BY Clayton Boldt, Ph.D.

The route a cancer takes from its earliest stages to advanced disease is a long and winding road. Often, the first mutations or changes that...

BY Clayton Boldt, Ph.D.

First discovered in the 1980s, exosomes are microscopic spherical packages, called vesicles, released by all cells. Their normal role in the...

BY Clayton Boldt, Ph.D.

Adoptive cellular therapy is a form of immunotherapy that uses cells from our immune systems, such as T cells, as a treatment for cancer. The immune cells are usually isolated from a patient, expanded and, in some cases, engineered to enhance their natural abilities to eliminate cancer.

This field has grown significantly in recent years with the FDA approval of chimeric antigen receptor (CAR) T cell therapies for certain patients...

BY Clayton Boldt, Ph.D.

Stomach and esophageal cancers are diagnosed in more than 40,000 people each year in the U.S. Most of these cases aren’t detected until the...

BY Clayton Boldt, Ph.D.

Discovering and developing new treatments for cancer is a difficult process with many obstacles. These challenges can slow the process of...

BY Clayton Boldt, Ph.D.

Targeted therapies are designed to work against specific vulnerabilities in a cancer cell.

The targeted therapy drug venetoclax is...

BY Clayton Boldt, Ph.D.

For patients with pancreatic cancer, the benefits from immunotherapy treatments with immune checkpoint inhibitors or cell therapies have been...

BY Clayton Boldt, Ph.D.

Last updated on Nov. 10, 2022

Immunotherapy is a treatment option for a growing number of cancers. Unlike traditional treatments like...

BY Clayton Boldt, Ph.D.

Minimal residual disease (MRD) is a term commonly used with blood cancers that describes a small fraction of cancer cells that remain or come...